GVHD (CGVHD) recently proposed criteria for diagnosis and assessment of overall CGVHD severity. We retrospectively reviewed 54 consecutive patients diagnosed with CGVHD between January 2002 and December 2005 after sibling donor transplant to assess the applicability of the new criteria in prognosticating survival and transplant-related mortality (TRM). A total of 8 patients (15%) were reclassified as late onset/ persistent or recurrent acute GVHD (late aGVHD), 15 (28%) had overlap syndrome and 31 (57%) had classic CGVHD. Three-year overall survival was worse in patients with late aGVHD (3-year probability 25% (95% CI 4-56%)) followed by overlap syndrome (3-year probability 87% (95% CI 56-96%)) and CGVHD (3-year probability 75% (95% CI 54-87%)); P ¼ 0.001. Among patients with overlap syndrome and CGVHD, a trend towards worse survival was seen in patients with severe disease (3-year probability 57.3% (95% CI 21-82%)) as compared to mild þ moderate disease (3-year probability 85.1% (95% CI 68-94)); P ¼ 0.1. This analysis, undertaken in a contemporary cohort of related donor recipients, indicates that the consensus guidelines are applicable to this population of CGVHD patients.
Introduction
Chronic GVHD (CGVHD) is a multiorgan disorder resembling autoimmune diseases, 1, 2 and is the leading cause of late nonrelapse mortality (transplant-related mortality, TRM) after hematopoietic stem cell transplant (HSCT). 3 The disease usually, but not always manifests after 100 days post transplant. Clinical syndromes resembling acute GVHD (aGVHD) 4, 5 are increasingly recognized beyond 100 days after HSCT 6, 7 and may be labeled as CGVHD. In addition, patients with aGVHD may progress to develop CGVHD with distinctive signs and symptoms of both acute and chronic GVHD. In addition, the old grading system of limited versus extensive GVHD was designed to identify patients needing systemic immune suppression and does not capture the severity of individual organ involvement. 2 Several grading schemes [8] [9] [10] [11] can predict survival following CGVHD. However, all lack consistent scoring and assessment of each involved organ to determine the overall severity of the disease. Recognizing these limitations, the diagnosis and staging working group of the NIH Consensus Development Project on CGVHD 1 proposed standard criteria for diagnosis, organ scoring and global assessment of CGVHD severity. We retrospectively reviewed 54 consecutive patients with CGVHD to assess the applicability of these criteria.
Materials and methods
All consecutive patients undergoing sibling donor transplant between January 2002 and December 2005 (n ¼ 197) and diagnosed with CGVHD (n ¼ 54) were eligible for this study. All patients were enrolled into protocols approved by Institutional Review Board of University of Minnesota and patients or their guardians signed informed consents. This retrospective review of patients with CGVHD was also approved by the Institutional Review Board of University of Minnesota. Demographic information regarding all patients undergoing a hematopoietic cell transplant is prospectively entered in the University of Minnesota Bone Marrow Transplant Database. This includes dates of diagnosis of CGVHD, type of onset and organs involved at baseline, relapse, survival and cause of death. This was supplemented by chart reviews for CGVHD-specific information including presenting symptoms and signs in the organs involved including degree of functional impairment, performance status, biopsy and/or pertinent lab results (including liver function tests, WBC count with differential, hemoglobin, plt count, wt, pulmonary function tests, Schirmer's test), treatment given, any complications (including infections) and duration of immunosuppression. Data collection and entry were carried out by trained personnel. Diagnosis and grading were based on criteria in consensus guidelines. Patients were required to have at least one diagnostic manifestation of CGVHD 1 (includes the following-skin: poikiloderma, Each organ of involvement was scored as zero, one, two or three based on the degree of functional impairment in each organ as recommended in consensus guidelines. 1 Patients had mild CGVHD if they had only one or two organs involved (except the lungs) with no clinically significant functional impairment (maximum score of one in all organs); moderate CGVHD included patients with at least one organ or site with clinically significant but no major disability (maximum score two in any organ) or three or more organs or sites with no clinically significant functional impairment (maximum score of one in all organs or sites). A lung score of one was considered as moderate CGVHD. Severe CGVHD included patients with major disability caused by CGVHD (score of three in any organ or site) or a lung score of two or greater.
Statistical analysis
Demographic and transplant related information were calculated as proportions. Survival after onset of CGVHD was estimated by Kaplan-Meier method. 12 The cumulative incidence of TRM was estimated by treating relapse as a competing risk. 13 Comparison of survival and TRM between subgroups was performed using log-rank test.
Results and discussion
A total of 54 consecutive patients with CGVHD were reviewed. Of all 54 patients (cumulative incidence 28% (95% CI 22-34%)), 8 (15%) were reclassified as late aGVHD. Table 1 provides a description of their demographic and CGVHD characteristics. Among the late aGVHD group, five had persistent aGVHD, two late onset aGVHD without any prior aGVHD and one had recurrent aGVHD. Figure 1a gives a description of prior acute GVHD in the three groups. Amongst the remaining 46 patients, 15 (28%) had overlap syndrome and 31 (57%) had classic CGVHD. Most of the patients (73%) with overlap syndrome had a progressive onset, whereas the majority of patients (87%) with CGVHD had a de novo or quiescent onset of disease (Figure 1b) . These 46 patients (overlap þ CGVHD) were graded as mild, moderate and severe. A total of 6 patients (13%) had mild disease (3 overlap, 3 CGVHD), 29 (63%) moderate disease (8 (28%) overlap, 21 (72%) CGVHD) and 11 (24%) severe disease (4 (36%) overlap, 7 (64%) CGVHD) ( Figure 2 ). Time to CGVHD (from transplant) was shortest in late aGVHD group (median 3.7 months (range 3.4-4.6 months)) versus overlap (4.6 months (range 2.9-8.2 months)) and CGVHD (6.3 months (range 3.1-21.2 months)). Patients with late aGVHD presented with manifestations resembling aGVHD with skin/gastrointestinal (GI)/liver involvement but no manifestations of CGVHD. Amongst patients with overlap syndrome, oral cavity and GI tract were the most frequently involved organs, whereas in patients with CGVHD, mouth and eyes were most frequently involved (Table 1) . Skin sclerosis was seen in 3 patients (2 CGVHD, 1 overlap) and lichenoid changes were seen in 12 (8 CGVHD, 4 overlap). After a median follow-up of 35 months (range 4.3-59.2 months), 3-year probability of overall survival was significantly worse in late aGVHD (25% (95% CI 4-56%)) as compared to overlap (87% (56-96%)) and CGVHD (75% (54-87%), P ¼ 0.001) (Figure 3a) . A total of 15 patients died at 1.2-24.6 months after onset of CGVHD. Of these, eight patients died of relapse or progressive malignancy (three late aGVHD, five CGVHD) Consensus guidelines applied to CGVHD cohort M Arora et al and seven patients died of complications secondary to GVHD (three late aGVHD, two CGVHD, two overlap). Amongst patients with overlap and CGVHD (n ¼ 46), similar survival was seen between mild and moderate disease. However, patients with severe disease had a trend to worse survival as compared to mild plus moderate disease (3-year probability of survival 85.1% (68-94%) versus 57.3% (21-82%)) (Figure 3b ). Similarly, 3-year cumulative incidence of TRM was higher in patients with late aGVHD (38% (9.4-66.6%)) versus overlap syndrome (13.3% (0-26.6%)) or CGVHD (6.5% (0-13%)), P ¼ 0.003 (Figure 3c) . A trend towards greater TRM was seen in patients with severe GVHD (18.3% (0-36.4)) versus mild þ moderate GVHD (6% (0-14%)) ( Figure 3d) . We compared the distribution of organ involvement in patients with late aGVHD with University of Minnesota historical cohort. 14 As shown in Figure 4 , patients reclassified as late aGVHD were less likely to have skin involvement and had more frequent GI and liver involvement as compared to the older cohort of patients with acute GVHD. This may reflect the organ distribution in patients with more refractory disease in patients with persistent or recurrent acute GVHD. Our data suggest that about 15% of patients with CGVHD may be misdiagnosed and have late aGVHD and that these patients with late, persistent or recurrent aGVHD have significantly worse survivals than do patients with CGVHD or overlap syndrome. This finding is similar to the recent analysis by Jagasia et al. 15 Grading of overlap syndrome or CGVHD shows that severe disease occurs with equal frequency in patients with overlap (27%) syndrome or CGVHD (22%). The patients with severe disease had worse survivals and higher TRM as compared to mild þ moderate CGVHD. Our center's contemporary experience identifies clinical value in the new diagnostic classification in identifying patients at high risk of death. The analysis is hampered by its retrospective nature (and is hence dependent upon accuracy and availability of medical records), and is therefore restricted to a smaller more contemporary cohort where detailed information could be obtained. Further prospective studies validating these diagnostic criteria and testing new therapies in the defined subpopulations are anticipated. Prospective trials focused on CGVHD should exclude patients with late aGVHD. 
